Study: Birth control pill use may decreases risk of urinary incontinence
WASHINGTON A new study from Sweden published Wednesday found that users of oral contraception have significantly reduced rates of urinary incontinence compared with women who used other forms of contraception.
Researchers at the Karoliska Institute and at Gothenburg University used the Swedish Twin Registry to examine the relationship between the use of oral contraceptives and urinary incontinence. After using statistical methods to control for factors such as age, Body Mass Index and ever having been pregnant, the data showed that the women who had used oral contraceptives had lower rates of lower urinary tract symptoms than non-users.
“With so many women using oral contraceptives, it is vital that we continue to fully understand their non-contraceptive effects, both positive and negative,” stated Dale McClure, president of the American Society for Reproductive Medicine. “This kind of research will help us better advise our patients as they make decisions about contraception, or possibly seek to avoid urinary tract problems.”
Amgen releases results of bone loss trial
THOUSAND OAKS, Calif. Amgen on Tuesday announced the publication of results from two pivotal phase 3 studies investigating the safety and effectiveness of denosumab at reducing fracture risk in more than 7,800 women with postmenopausal osteoporosis and in more than 1,400 men with nonmetastatic prostate cancer undergoing androgen deprivation therapy leading to bone loss.
In both studies, published Aug. 11 in The New England Journal of Medicine, patients receiving twice-yearly denosumab experienced significant increases in bone mineral density compared with placebo, associated with more than 60% reduction in vertebral fracture in both patient populations.
“The discovery of the RANK Ligand pathway represents a significant advance in the understanding of bone biology,” stated Roland Baron, professor and chair of department of Oral Medicine, Infection and Immunity at the Harvard School of Dental Medicine. “These results demonstrate that targeting the RANK Ligand pathway with denosumab could represent a promising new approach in two different disease settings characterized by bone loss.”
Claritin expands line with eye drop for allergy sufferers
KENILWORTH, N.J. Schering-Plough announced the launch of Claritin Eye, an antihistamine eye drop strong enough to control itchy eyes all day or all night.
Claritin Eye works in minutes to relieve the itch of allergy eyes for up to 12 hours with just one drop; is available without a prescription and can be found in most food, drug or mass retailers.
“Itchy eyes are an extremely bothersome symptom for allergy sufferers and can be caused by indoor or outdoor allergens such as dust, pet dander, mold or pollen. Claritin Eye relieves the itch at the source by blocking the histamine that causes itchy eyes,” said John O’Mullane, group VP research and development, Schering-Plough Consumer Health Care. “We’re excited to add this new allergy eye product to the line of non-drowsy Claritin allergy products.”
To support the introduction of the new product, the makers of Claritin will kick off the launch with national advertising as well as launching the brand’s first official Facebook page. The page features a “Claritin Eye Makeover” application where fans are invited to upload their favorite photos and use the application to clear the red eye in their pictures. The page, available at Facebook.com/claritineye, offers resources for allergy sufferers including facts, tips and a photo gallery where visitors can show how they “Live Claritin Clear.”
For more information on allergies and non-drowsy treatment options, visit Claritin.com.